SU-DHL-4/SU-DHL-4/SU-DHL-4/人B细

SU-DHL-4/SU-DHL-4细胞系/SU-DHL-4细胞株/SU-DHL-4人B细胞淋巴瘤

Cell line name SU-DHL-4

Synonyms SUDHL4; Sudhl4; SUDHL-4; Sudhl-4; SuDHL 4; SUD-4; SUD4; SU4; Stanford University-Diffuse Histiocytic Lymphoma-4; DHL-4; DHL4

Accession CVCL_0539

Resource Identification Initiative To cite this cell line use: SU-DHL-4 (RRID:CVCL_0539)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Population: Caucasian.

Doubling time: ~40 hours (DSMZ=ACC-495).

Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).

Omics: Array-based CGH.

Omics: Cell surface proteome.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Virome analysis using RNAseq.

Derived from site: In situ; Peritoneal effusion; UBERON=UBERON_0001268.

PubMed=17363600; DOI=10.1158/0008-5472.CAN-06-3254

Strauss S.J., Higginbottom K., Juliger S., Maharaj L., Allen P., Schenkein D., Lister T.A., Joel S.P.

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.

Cancer Res. 67:2783-2790(2007)

 

PubMed=18357372; DOI=10.3892/or.19.4.889

Pop I., Pop L., Vitetta E.S., Ghetie M.-A.

Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.

Oncol. Rep. 19:889-895(2008)

 

PubMed=19278952; DOI=10.1182/blood-2009-01-202028; PMCID=PMC3401058

Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Blood 113:6681-6690(2009)

 

PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535

Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Nature 463:88-92(2010)

 

PubMed=20628145; DOI=10.1182/blood-2010-05-282780; PMCID=PMC2995356

Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Blood 116:3268-3277(2010)

 

PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744

Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E., Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.

Blood 117:200-210(2011)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=23292937; DOI=10.1073/pnas.1205299110; PMCID=PMC3557051

Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W.W.-L., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.

Genetic heterogeneity of diffuse large B-cell lymphoma.

Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)

 

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145

Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

J. Virol. 89:713-729(2015)